Ascenta Capital — Full Portfolio
9 tracked investments · listed companies and verified rows first
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Co-Founder & CEO)inFred Manby(Co-Founder & CTO)inThomas Miller(Founder)inNeil Josephson(Chief Medical Officer)inPete Olson(Chief Scientific Officer)inMichael Secora(Chief Financial Officer and Chief Corporate Development Officer)in
Co-investorsAbingworthCatalio Capital ManagementAlumni VenturesCatalio Capital Management, LPCoatue ManagementEisai Innovation, Inc.+4 more
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.
BiotechDeep TechMedical DevicesMenlo Park, US
Mani Subramanian(Executive Officer, Director)Gangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers
BoardMatthew Young(Director)inSrinivas Akkaraju(Director)
Co-investorsLongitude CapitalSamsara BioCapitalF-Prime Capital
TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.
BiotechDeep TechHealthtechLexington, US
Patrick Trojer(President & CEO, Co-founder)
Co-investorsAtlas VentureBessemer Venture PartnersLightspeed Venture PartnersPfizer VenturesRA CapitalPfizer Venture Investments
San Diego, US
Board seatLorence Kim· per SEC Form D · $200M raise · filed Aug 2023
Co-investorsLAVLilly Asia VenturesSilverArc PrivateTCG Crossover
Faction is a venture capital firm that invests in cryptocurrency and blockchain projects at the seed and series A stages, focusing on entrepreneurs building fundamental utility across the technology stack.
BiotechCrypto & Web3New York, US
Oren Harnevo(Executive Officer, Director)Ronald Bianchini, Jr.(Executive Officer, Director)Roneil Rumburg(Cofounder)Ohad Finkelstein(Director)Christina Calvaneso(Executive Officer)Brian Pozesky(Executive Officer)
Board seatLorence Kim· per SEC Form D · filed Dec 2023
Co-investorsAccelAdaverseAlephAxeleo CapitalBluebird VenturesBright Pixel Capital+36 more
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)in
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)
Board seatLorence Kim· per SEC Form D · $121.1M raise · filed Aug 2024
Co-investorsActivant CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess FundGreatPoint Ventures+6 more
BiotechWaltham, US
Joshua Resnick(Director)Milind Deshpande(Executive Officer, Director)Simon Read(Director)
BoardDavid Grayzel(Director)
Board seatLorence Kim· per SEC Form D · $120.1M raise · filed Dec 2025
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.
BiotechDigital HealthHealthtech
Vishal Patelin
Co-investorsAtlas VentureBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMedFidelity Investments+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.